Harmony Biosciences Holdings, Inc. $HRMY Stock Holdings Boosted by 683 Capital Management LLC

683 Capital Management LLC lifted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 47.2% in the 4th quarter, HoldingsChannel reports. The firm owned 415,000 shares of the company’s stock after purchasing an additional 133,000 shares during the quarter. Harmony Biosciences makes up 0.7% of 683 Capital Management LLC’s portfolio, making the stock its 22nd largest holding. 683 Capital Management LLC’s holdings in Harmony Biosciences were worth $15,529,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of HRMY. Public Sector Pension Investment Board lifted its holdings in Harmony Biosciences by 41.6% in the third quarter. Public Sector Pension Investment Board now owns 185,803 shares of the company’s stock worth $5,121,000 after purchasing an additional 54,605 shares during the period. Ruffer LLP acquired a new stake in Harmony Biosciences in the fourth quarter worth about $1,536,000. American Century Companies Inc. lifted its holdings in Harmony Biosciences by 11.2% in the third quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock worth $46,013,000 after purchasing an additional 168,145 shares during the period. State of New Jersey Common Pension Fund D acquired a new stake in Harmony Biosciences in the third quarter worth about $1,572,000. Finally, CX Institutional lifted its holdings in Harmony Biosciences by 19.7% in the fourth quarter. CX Institutional now owns 275,809 shares of the company’s stock worth $10,321,000 after purchasing an additional 45,376 shares during the period. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $33.77 on Thursday. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.87. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 13.62, a PEG ratio of 0.24 and a beta of 0.96. The firm has a 50-day moving average of $31.23 and a two-hundred day moving average of $33.09.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The firm had revenue of $215.39 million for the quarter, compared to analysts’ expectations of $220.84 million. During the same period in the prior year, the company posted $0.78 earnings per share. Harmony Biosciences’s quarterly revenue was up 16.6% compared to the same quarter last year. As a group, analysts expect that Harmony Biosciences Holdings, Inc. will post 3.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on HRMY. Deutsche Bank Aktiengesellschaft downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective for the company. in a report on Monday, February 23rd. Zacks Research raised shares of Harmony Biosciences from a “strong sell” rating to a “hold” rating in a report on Friday, May 1st. Wall Street Zen downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Bank of America cut their price target on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a report on Wednesday, February 25th. Finally, Weiss Ratings downgraded shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $40.89.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.